CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
Pulsatility Physiological secretion The combination preserves the natural pulsatile secretion of GH, unlike exogenous GH
Patients should not use Tesamorelin or growth hormone-related peptides without a review of labs, medical history, medications, glucose markers, cancer history, and body composition goals
It is synthesized from glutamate, cysteine and glycine
SAMe Dose Give: 50 mg per 20 lbs of body weight daily SAMe is one of the most important liver-support supplements because it directly supports glutathione production
